Skip to main content

Table 1 Characteristics of all patients classified as having nonradiographic axial spondyloarthritis at inclusion in SCQM

From: Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort

Parameter A. All nr-axSpA patients B. All nr-axSpA patients excluding patients with co-morbid FM
N, 495 Men, N = 231 Women, N = 264 p N, 470 Men, N = 227 Women, N = 243 p
Age, years 495 36.6 (10.9) 38.2 (10.7) 0.09 470 36.4 (10.9) 38.1 (10.7) 0.09
Age at symptom onset, years 481 28.3 (8.4) 28.7 (9.1) 0.65 456 28.2 (8.4) 28.6 (9.0) 0.65
Symptom duration, years 481 8.3 (9.2) 9.6 (9.8) 0.10 456 8.2 (9.2) 9.5 (9.8) 0.12
Diagnostic delay, years 480 4.7 (7.6) 6.0 (7.8) 0.005 455 4.7 (7.5) 6.0 (7.8) 0.01
HLA-B27 positive, % 453 76.5 67.0 0.03 430 77.0 68.2 0.05
Positive family history for spondyloarthritis, % 417 32.0 40.5 0.08 393 32.1 42.0 0.05
Prior sacroiliitis on MRI, % 477 52.9 58.7 0.23 453 53.9 58.5 0.34
BASDAI 430 4.6 (2.2) 5.3 (2.1) 0.003 412 4.6 (2.2) 5.1 (2.1) 0.02
• BASDAI 1 (fatigue) 436 4.7 (2.8) 6.0 (2.4) < 0.001 418 4.7 (2.8) 5.9 (2.4) < 0.001
• BASDAI 2 (back pain) 436 5.9 (2.7) 6.5 (2.5) 0.03 418 5.9 (2.7) 6.3 (2.5) 0.10
• BASDAI 3 (joint pain/swelling) 435 3.6 (3.1) 4.2 (3.1) 0.04 417 3.6 (3.1) 4.1 (3.1) 0.07
• BASDAI 4 (enthesitis) 433 4.2 (3.3) 5.0 (3.1) 0.02 415 4.2 (3.3) 4.8 (3.0) 0.04
• BASDAI 5 (intensity of morning stiffness) 434 5.2 (3.0) 5.4 (3.1) 0.65 416 5.3 (3.0) 5.2 (3.1) 0.96
• BASDAI 6 (duration of morning stiffness) 433 4.0 (2.9) 4.1 (2.9) 0.68 415 4.0 (2.9) 4.0 (2.9) 0.99
Physician Global Assessment 481 3.7 (2.2) 3.8 (2.0) 0.49 412 3.7 (2.2) 3.7 (2.0) 0.86
Patient Global Assessment 430 5.3 (2.9) 5.6 (2.8) 0.27 412 5.3 (2.9) 5.5 (2.8) 0.54
ASDAS 402 2.9 (1.0) 2.9 (0.9) 0.23 386 2.9 (1.0) 2.9 (0.9) 0.49
CRP (mg/l), median (IQR) 463 4.0 (1.0; 8.0) 4.0 (2.0; 8.0) 0.86 441 4.0 (1.1; 8.0) 4.0 (2.0; 8.0) 0.96
Elevated CRP, % 459 26.5 26.6 1.00 437 26.5 26.1 1.00
BASFI 435 2.8 (2.4) 3.1 (2.5) 0.16 416 2.8 (2.4) 2.9 (2.4) 0.54
BASMI 473 1.3 (1.4) 1.3 (1.3) 0.98 449 1.4 (1.4) 1.3 (1.2) 0.72
EQ-5D 431 61.4 (22.5) 59.7 (20.1) 0.34 412 61.3 (22.6) 61.2 (19.4) 0.78
IBP according to ASAS, % 462 80.5 77.3 0.43 437 80.6 77.0 0.41
Spinal MRI inflammation, % 476 26.9 24.9 0.67 452 26.9 23.6 0.45
Spinal radiographic changes, % 476 6.3 3.6 0.20 452 5.9 3.0 0.17
Current peripheral arthritis,% 489 35.8 39.2 0.46 464 36.0 38.9 0.57
Number of swollen joints 481 0.7 (1.9) 0.9 (2.3) 0.38 457 0.7 (1.9) 0.7 (1.8) 0.54
Current enthesitis, % 483 64.0 79.6 < 0.001 459 63.8 78.3 < 0.001
Modified MASES 481 1.9 (2.5) 3.2 (3.4) < 0.001 457 1.8 (2.5) 2.9 (3.1) < 0.001
Co-morbid fibromyalgia, % 307 2.7 13.1 < 0.001
Dactylitis ever, % 492 10.9 11.4 0.89 468 10.6 12.0 0.66
Uveitis ever, % 434 18.1 13.1 0.18 410 18.4 12.9 0.14
Psoriasis ever, % 373 9.1 9.1 1.00 351 9.3 8.4 0.85
Inflammatory bowel disease ever, % 427 6.0 7.9 0.46 403 5.6 8.2 0.33
Taking NSAIDs, % 471 87.3 90.4 0.31 447 87.6 89.6 0.55
Taking methotrexate, % 495 5.2 10.2 0.04 470 5.3 9.9 0.08
Taking sulfasalazine, % 495 4.8 6.1 0.56 470 4.8 6.2 0.55
Taking TNFi, % 495 14.7 15.5 0.90 470 14.5 15.2 0.90
Ever TNFi, % 495 68.0 72.0 0.78 470 67.4 70.8 0.80
Current smoking, % 432 32.0 30.2 0.75 413 32.0 28.3 0.45
Body mass index 483 25.7 (3.9) 24.3 (4.5) < 0.001 458 25.6 (3.9) 24.1 (4.2) < 0.001
Education, % 462    0.46 440    0.52
• Compulsory   15.8 19.8    15.2 18.3  
• Vocational   56.7 51.8    57.4 52.4  
• University   27.4 28.3    27.5 29.3  
Absenteeism within last year, % 389 53.9 44.0 0.12 372 53.9 43.2 0.10
  1. All patients with nr-axSpA are presented in A, while patients with co-morbid fibromyalgia are excluded in B. Except where indicated otherwise, values are the mean (SD). Data in bold are statistically significant. ASAS Assessment of SpondyloArthritis international Society, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, EQ-5D EuroQol 5-domains, FM fibromyalgia, HLA-B27 human leucocyte antigen B27, IBP inflammatory back pain, MASES Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers to the inclusion of the plantar fascia in the count, MRI magnetic resonance imaging, nr-axSpA nonradiographic axial spondyloarthritis, NSAIDs nonsteroidal anti-inflammatory drugs, TNFi tumor necrosis factor inhibitor